Cell News and Research

RSS

Cavit Sciences and McCoy form an agreement to finalize their merger

Cavit management has been negotiating with Randall McCoy and Joe Connell principle owners of McCoy Enterprises LLC to merge our companies. Maggie Smyth, CEO of Cavit states, “We all feel very good about this fit so we have added a breakup clause to show our commitment to each other”.

2 Sep 2009

ZymoGenetics to provide company updates at upcoming investor conferences

ZymoGenetics, Inc. announced today that senior executives will provide updates on company activities at two upcoming investor conferences.

2 Sep 2009

Selexis SA and NKT Therapeutics sign research services agreement

Selexis SA ("Selexis") and NKT Therapeutics, Inc. ("NKTT") announce today that they have entered into a research services agreement whereby Selexis will screen antibody variants and generate high performance CHO-based production cell lines using their novel platform named INTEGRA-D2M(TM).

2 Sep 2009

Gene causing periodontitis, rheumatoid arthritis and osteoporosis identified

Investigators at Hospital for Special Surgery, collaborating with researchers from other institutions, have contributed to the discovery that a gene called interferon regulator factor-8 (IRF-8) is involved in the development of diseases such as periodontitis (gum disease), rheumatoid arthritis and osteoporosis. The study, which will be published online August 30, ahead of print, in the journal Nature Medicine, could lead to new treatments in the future.

2 Sep 2009

TRAF6 protein plays a role in cell growth and carcinogenesis, says researchers

The mainstay immune system protein TRAF6 plays an unexpected, key role activating a cell signaling molecule that in mutant form is associated with cancer growth, researchers at The University of Texas M. D. Anderson Cancer Center report in the Aug. 28 edition of Science.

2 Sep 2009

STEMCELL Technologies to conduct a two-day stem cell training program

STEMCELL Technologies has announced the schedule for their fall training program. This includes 2-day courses on mesenchymal stem cell biology (October 2nd and 3rd), mammary stem cell biology (October 17th and 18th), neural stem cell biology (October 30th and 31st), hematopoietic stem cell biology (October 30th and 31st), and human embryonic and induced pluripotent stem cell biology (November 14th and 15th).

2 Sep 2009

Monsanto sings a non-exclusive research and commercial license agreement with Cellectis

Monsanto Company (NYSE:MON) today announced a non-exclusive research and commercial license agreement with France-based Cellectis S.A. (Paris:ALCLS), a biotechnology company specialized in genome engineering, for broad use of its meganuclease technology in plants.

2 Sep 2009

$Adult stem cell treatments for severe limb ischemia and refractory coronary ischemia discussed$

Adult stem cell treatments for severe limb ischemia and refractory coronary ischemia discussed

This week TCA Cellular Therapy`s Medical Director Gabriel Lasala, M.D. presents advances in adult stem cell treatments for severe limb ischemia and refractory coronary ischemia at the European Society of Cardiology Congress in Barcelona, Spain.

2 Sep 2009

New study on behaviour of telomeres during cell division in cancerous human cells

A process that limits the number of times a cell divides works much differently than had been thought, opening the door to potential new anticancer therapies, researchers at UT Southwestern Medical Center report in the Aug. 7 issue of the journal Cell.

2 Sep 2009

Genes that regulate the energy consumption of cells have a different structure and expression in diabetics

Genes that regulate the energy consumption of cells have a different structure and expression in type II diabetics than they do in healthy people, according to a new study from the Swedish medical university Karolinska Institutet published in Cell Metabolism.

2 Sep 2009

T cells influence aggressive immune cells by regulating the chemical environment between cells

University of Michigan scientists say they have uncovered a fundamentally new mechanism that holds in check aggressive immune cells that can attack the body's own cells. The findings open a new avenue of research for future therapies for conditions ranging from autoimmune diseases to organ transplants to cancer.

2 Sep 2009

Study reveals that antibiotics used to treat a variety of bacterial infections could cause double vision

Highlights of September's Ophthalmology, the journal of the American Academy of Ophthalmology (Academy), include a 2009 review by the Academy of the safety and efficacy of a widely used corneal transplant procedure and a warning about an unusual but serious reaction to systemic fluoroquinolones, a class of antibiotics used to treat a variety of bacterial infections.

2 Sep 2009

Nuvo Research's co-operative drug development project with Fraunhofer Institute for developing WF10

Nuvo Research Inc., a Canadian drug development company focused on the research and development of drug products that are delivered to and through the skin using its topical and transdermal drug delivery technologies, and on the development of its immune modulating drug candidate WF10, today announced a co-operative drug development project with the Fraunhofer Institute for Cell Therapy and Immunology IZI in Leipzig, Germany for the preclinical and clinical development of WF10 as a potential treatment for Allergic Rhinitis.

2 Sep 2009

New ARRA-funded research on white blood cell functioning

The American Recovery and Reinvestment Act (ARRA) has provided funding for new research to learn more about how white blood cells work. Jonathan Reichner, PhD, of the department of surgery at Rhode Island Hospital has received a grant from the National Institutes of Health with funding through the American Recovery and Reinvestment Act. Reichner's hope is that the research will lead to new immune-enhancing therapies, with potential implications for improvements in both cancer treatment and controlling inflammation accompanying injury and infection.

2 Sep 2009

Nanodiamonds: A novel gene delivery technology

Gene therapy holds promise in the treatment of a myriad of diseases, including cancer, heart disease and diabetes, among many others. However, developing a scalable system for delivering genes to cells both efficiently and safely has been challenging.

2 Sep 2009

Vitro Diagnostics develops technology and products for cell-based cancer therapy

Vitro Diagnostics, Inc. (OTCBB: VODG), dba Vitro Biopharma, announced advances in its adult stem cell products and technology with application to cell-based therapy of cancer. With the passing of Senator Edward Kennedy from brain cancer, we are reminded of such aggressive cancers without effective treatment.

2 Sep 2009

Grant awarded to two researchers to study the role of GLP-1 in people at risk for or with diabetes

The American Diabetes Association Research Foundation has selected two scientists, University of Virginia Health System researcher Zhenqi Liu, MD, and Stanford University School of Medicine researcher Gerald Reaven, MD, to receive the American Diabetes Association-Novo Nordisk Clinical/Translational Research Award. This $1.2 million grant program supports efforts to study the effects of intestinal hormones, such as glucagon-like peptide-1 (GLP-1), on obesity and pre-diabetes, two risk factors for type 2 diabetes and cardiovascular disease.

2 Sep 2009

Children's Hospital Oakland converts to Masimo Rainbow SET Pulse CO-Oximetry technology

Masimo (Nasdaq: MASI), the inventor of Pulse CO-Oximetry(TM) and Measure-Through Motion and Low-Perfusion pulse oximetry, announced today that Children's Hospital & Research Center Oakland has completed its system-wide conversions to Masimo Rainbow SET Pulse CO-Oximetry technology.

2 Sep 2009

Pathogenic microbes can suppress immune system in newborns

Group B Streptococcus (GBS), a bacterial pathogen that causes sepsis and meningitis in newborn infants, is able to shut down immune cell function in order to promote its own survival, according to researchers at the University of California, San Diego School of Medicine and the Skaggs School of Pharmacy and Pharmaceutical Sciences.

2 Sep 2009

Heidelberg neuropathologists detect astrocytomas that can deactivate the "death receptor"

Malignant brain tumors often fail to respond to promising new medication. Researchers in Heidelberg have discovered a mechanism and a tumor marker for the development of this resistance. A "death receptor" can possibly provide information as to how great the chances of success are for chemotherapy. At the same time, it offers a new approach for promising brain tumor therapy.

2 Sep 2009

Cell News and Research

Cavit Sciences and McCoy form an agreement to finalize their merger

ZymoGenetics to provide company updates at upcoming investor conferences

Selexis SA and NKT Therapeutics sign research services agreement

Gene causing periodontitis, rheumatoid arthritis and osteoporosis identified

TRAF6 protein plays a role in cell growth and carcinogenesis, says researchers

STEMCELL Technologies to conduct a two-day stem cell training program

Monsanto sings a non-exclusive research and commercial license agreement with Cellectis

Adult stem cell treatments for severe limb ischemia and refractory coronary ischemia discussed

New study on behaviour of telomeres during cell division in cancerous human cells

Genes that regulate the energy consumption of cells have a different structure and expression in diabetics

T cells influence aggressive immune cells by regulating the chemical environment between cells

Study reveals that antibiotics used to treat a variety of bacterial infections could cause double vision

Nuvo Research's co-operative drug development project with Fraunhofer Institute for developing WF10

New ARRA-funded research on white blood cell functioning

Nanodiamonds: A novel gene delivery technology

Vitro Diagnostics develops technology and products for cell-based cancer therapy

Grant awarded to two researchers to study the role of GLP-1 in people at risk for or with diabetes

Children's Hospital Oakland converts to Masimo Rainbow SET Pulse CO-Oximetry technology

Pathogenic microbes can suppress immune system in newborns

Heidelberg neuropathologists detect astrocytomas that can deactivate the "death receptor"

Improve fermentation and cell culture performance with real-time gas analysis eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo